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Abstract
Hyperinsulinemic hypoglycemia (HH) is characterized by unregulated insulin release, leading to persistently low blood
glucose concentrations with lack of alternative fuels, which increases the risk of neurological damage in these patients. It
is the most common cause of persistent and recurrent hypoglycemia in the neonatal period. HH may be primary,
Congenital HH (CHH), when it is associated with variants in a number of genes implicated in pancreatic development
and function. Alterations in fifteen genes have been recognized to date, being some of the most recently identified
mutations in genes HK1, PGM1, PMM2, CACNA1D, FOXA2 and EIF2S3. Alternatively, HH can be secondary when
associated with syndromes, intra-uterine growth restriction, maternal diabetes, birth asphyxia, following gastrointestinal
surgery, amongst other causes. CHH can be histologically characterized into three groups: diffuse, focal or atypical.
Diffuse and focal forms can be determined by scanning using fluorine-18 dihydroxyphenylalanine-positron emission
tomography. Newer and improved isotopes are currently in development to provide increased diagnostic accuracy in
identifying lesions and performing successful surgical resection with the ultimate aim of curing the condition. Rapid
diagnostics and innovative methods of management, including a wider range of treatment options, have resulted in a
reduction in co-morbidities associated with HH with improved quality of life and long-term outcomes. Potential future
developments in the management of this condition as well as pathways to transition of the care of these highly
vulnerable children into adulthood will also be discussed.
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1 Introduction
Glucose is one of the principal energy substrates, providing
half of the body’s total energy requirements. As the brain can
neither synthesize nor store more than a fewminutes supply of
glucose, its function is solely dependent on maintenance of
normal glucose concentrations in the circulation. An abnor-
mally reduced concentration of glucose in the blood is referred
to as hypoglycemia. It is a medical emergency and can lead to
symptoms due to neuroglycopenia [1].
In healthy individuals, maintenance of a normal plasma
glucose concentration relies on a tightly controlled balance
between glucose production (dietary intake, glycogenolysis,
gluconeogenesis) and its utilization by the tissues (glycolysis,
glycogenesis, conversion to fatty acids). A normal endocrine
system is essential for integrating and modulating substrate
mobilization, interconversion, and utilization. In addition,
the endocrine system interacts with metabolic pathways that
rely critically on functionally intact enzymes. There are two
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types of metabolic hormones affecting blood glucose concen-
trations – an anabolic hormone (insulin), which decreases
blood glucose, and several catabolic hormones (such as
glucagon, cortisol and catecholamines) which increase blood
glucose concentrations.
Hyperinsulinemic hypoglycemia (HH) is the commonest
cause of persistent hypoglycemia in infants and children [2]
and it can be transient –associated to risk factors- or permanent
–linked to genetic mutations-. The risk of permanent brain
injury in infants with HH continues to be as high as 25–50%
due to delays in diagnosis and inadequate treatment. Despite
advances in genetics, improved modes of investigation, novel
management options and abrigding pediatric and adult follow-
up in holistic multidisciplinary transition clinics, significant
morbidity and mortality is still a major issue in children and
young adults with HH [3–5].
The present review has beenwritten using a comprehensive
and up- to -da t e l i t e r a tu re sea r ch on congen i t a l
hyperinsulinism/HH including the latest publications avail-
able in PubMed (last search in August 2019). It also incorpo-
rates clinical and laboratory experience from reference centers
for the diagnosis and management of HH, as well as available
data from on-going pharmaceutical trials.
2 normal blood glucose and hypoglycemia
2.1 Definition of normal blood glucose
Blood glucose concentrations of normal term neonates appro-
priate for gestational age may range between 1.4–6.2 mmol/l
(25–112mg/dl) during the first 72 h of life; however after that,
healthy children and adults will maintain blood glucose con-
centrations between 3.5–5.5 mmol/l (63–99 mg/dl) [6]. It is
difficult to numerically define hypoglycemia given that a sin-
gle cut-off value cannot suit all individuals in every situation.
Therefore operational thresholds are recommended which in-
dicate that in any baby with clinical signs of hypoglycemia,
blood glucose levels must be maintained over 2.6 mmol/l
(47 mg/dl) except for suspected cases of hyperinsulinemic
hypoglycemia in which 3.5 mmol/l (63 mg/dl) should be the
cut-off point [7]. However, the Pediatric Endocrinology
Society recommends that when a congenital disorder causing
hypoglycemia is suspected in a neonate and when confirmed
in older infants and children, the aim is to keep plasma glucose
concentrations over 3.9 mmol/l (70 mg/dl) [7].
2.2 Causes of hypoglycemia
For hypoglycemia to occur, the rate of appearance of
glucose into the plasma space must be less than its rate
of utilization [8]. This can be due to defective glucose
production, increased glucose utilization, or some
combination of the two. Excessive glucose utilization
due to hyperinsulinism (exogenous/endogenous) is one
o f t h e commone s t c a u s e s o f hypog l yc em i a .
Hypoglycemia can also occur due to deficiencies of
various counter regulatory hormones. The causes are
collected in Table 1.
Hereditary disorders caused by deficiency of specific en-
zymes involved inmobilization, interconversion, or utilization
of metabolic substrates frequently are associated with hypo-
glycemia. These enzymatic defects may involve carbohydrate,
amino acid, or fat metabolism and are individually rare; al-
most all are inherited as autosomal recessive traits [8].
3 HYPERINSULINEMIC hypoglycemia (HH)
HH is a condition caused by the upregulation of β-cell
secretion of insulin producing a hypoglycemic state.
Congenital hyperinsulinism (CHH) is the most common
cause of transient or permanent hypoglycemia and could
potentially be life threatening causing neurological dam-
age. Hence it requires quick and effective treatment and
management [8]. This disorder is rare and has an inci-
dence of around 1:40,000 births in the general popula-
tion [15]. CHH can occur due to genetic mutations and
one of the most common causes are defects in the β-
cell ATP-sensitive potassium (KATP) channels, known as
channelopathies [8]. KATP channels are comprised of
two subunits; the inward rectifying Kir6.2 channels
and the sulphonylurea receptor-1, SUR-1, which are
encoded for by the KCNJ11 (potassium voltage-gated
channel subfamily J member 11) and ABCC8 (ATP-
binding cassette transporter sub-family C member 8)
genes, respectively [16]. Both these subunits are sensi-
tive to the ADP/ATP nucleotide ratio and work together
to promote cell depolarization and eventual insulin se-
cretion. Mutations in the KCNJ11/ABCC8 genes are
known to cause defects in biogenesis/trafficking of these
subunits to the plasma membrane, thus causing HH.
4 Causes of HH
4.1 Transient forms of HH
Transient HH is a poorly defined term that refers to the
group of patients in whom HH spontaneously resolves
within a few days to approximately a week. However,
the cohort includes children requiring medications up to
6 months of life and is usually negative for a known
genetic etiology for HH [17]. It is associated with intra-
uterine growth retardation, erythroblastosis fetalis, peri-
natal asphyxia, maternal diabetes mellitus (gestational or
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insulin dependent) and after the maternal administration
of drugs such as sulphonylureas, and intravenous glu-
c o s e i n f u s i o n s du r i n g l a b o r [ 2 ] . Abno rma l
neurodevelopment is evident in one third of children
with transient forms of HH associated with perinatal
risk factors [5].
4.2 Permanent form of HH
A permanent form of HH, usually congenital (CHH), is where
children continue to need medical treatment even after
6 months of age. Various genetic causes have been identified,
however nearly 40–50% of children still remain genetically
unidentified [17].
4.2.1 Molecular basis of CHH
To date, at least 15 genes have been identified to be accom-
panied with CHH, which include ABCC8, KCNJ11, GLUD1,
GCK, HADH, SLC16A1, UCP2, HNF1A, HNF4A, HK1,
PGM1, PMM2, FOXA2, CACNA1D and EIF2S3.
Various modes of inheritance are observed. For some pa-
tients specific clinical characteristics, such as the presence of
hyperammonemia, can help guide molecular testing; however,
for most of the genetic subgroups there is an overlap in phe-
notype and as such testing of all the known genes is often
required.
KATP channel genes (ABCC8 and KCNJ11) The pancreatic KATP
channel is a key component of the insulin secretion pathway.
Table 1 Endocrine and metabolic
causes of Hypoglycemia -
Specific pathologies affecting
main metabolic and endocrine
pathways that can lead to hypo-
glycemia [5, 9–14, 61, 63]
Hyperinsulinism Transient
Infant of diabetic mother
Perinatal asphyxia
Rhesus hemolytic disease
Intrauterine growth restriction
HNF4A/HNF1A
Congenital
ABCC8/ KCNJ11/ GCK/ GDH/ HADH/ HNF4A/ HNF1A/ UCP2/
SLC16A1/PMM2/HK1/PGM1/FOXA2/CACNA1D/EIF2S3
Others
Post-prandial hyperinsulinemic hypoglycemia
Insulinoma
Munchausen’s by proxy
Exercise induced hyperinsulinemic hypoglycemia
Hypoinsulinemic hypoglycemia Activating AKT2 mutations
Counter-regulatory hormone
deficiency
Growth hormone deficiency
Adrenal insufficiency
Fatty acid oxidation disorders Medium chain acyl-CoA dehydrogenase deficiency
Long chain acyl-CoA dehydrogenase deficiency
Short chain acyl-CoA dehydrogenase deficiency
Defects in ketone body
synthesis/ utilization
HMG CoA synthase deficiency
HMG CoA lyase deficiency
Carnitine deficiency (primary
and secondary)
Carnitine palmitoyl transferase deficiency
(CPT 1 and 2), Carnitine deficiency
Gluconeogenic disorders Fructose-1, 6-bisphosphatase deficiency,
Phosphoenolpyruvate carboxykinase (PEPCK) deficiency
Pyruvate carboxylase deficiency
Glycogen storage disorders Glucose-6-phosphatase deficiency
Amylo 1–6 glucosidase deficiency
Glycogen synthase deficiency
Defects in glucose transport GLUT 1/2/3 transporters defects
Other metabolic conditions Galactosemia, Fructosemia, Tyrosinemia, Glutaric aciduria type 2, Maple
syrup urine disease, Propionic academia
Adenosine kinase deficiency
Mitochondrial respiratory chain disease
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Following glycolysis ATP binds to and closes the KATP channel
causing membrane depolarization, opening of calcium channel
and insulin exocytosis (Fig. 1). Loss of function variants in
ABCC8 and KCNJ11 are the most common cause of HH ac-
counting for 40–50% of cases [17–19](OMIM #601820 and
#256450). These variants exert their effects by 1) leading to a
loss of KATP channels at the plasma membrane via effects on
gene expression, protein synthesis, protein maturation, or mem-
brane trafficking or 2) by impairing the ability of SUR1 to reg-
ulate channel activity by reducing or abolishing channel activa-
tion by MgADP and/or MgATP [20, 21]. Recessively inherited
variants are the most common and usually result in medically
unresponsive HH. Dominant variants in both genes have also
been reported [22–24]. The functionally more severe dominant
variants cause diazoxide unresponsive HH requiring near-total
pancreatectomy whilst milder variants cause diazoxide-
responsive HH [25]. In some of the milder cases a bi-phasic
phenotype has been reported whereby HH remits in childhood
and diabetes is diagnosed in adulthood [26].
Glutamate dehydrogenase (GLUD1) Gain of function muta-
tions in GLUD1 gene, which encodes the mitochondrial en-
zyme glutamate dehydrogenase (GDH), cause leucine-
sensitive HH (OMIM #606762) [27]. Within the pancreatic
β-cell, leucine can activate GDH to catalyze the oxidative de-
amination of glutamate to α-ketoglutarate and ammonia. A-
ketoglutarate then enters the tricarboxylic acid cycle (TCA)
which generates ATP, ultimately leading to insulin exocytosis.
Disease-causing variants in GLUD1 cluster around allosteric
binding sites and act to reduce the sensitivity of GDH to
Fig. 1 Diagrammatic representation of β-cell function. Genetic defects
associated with CHH are included in red. Postprandial glucose is taken
into the β-cells via the glucose transporter 2 (GLUT2). Glucose then
enters the glycolysis pathway followed by mitochondrial citric acid cycle
(TCA) yielding the high-energy molecule, adenosine triphosphate (ATP).
ATP molecules travel to and inhibit the potassium-dependent ATP chan-
nels (KATP), which prevents influx of potassium resulting in membrane
depolarization. This triggers voltage-gated calcium channels to open and
influx of calcium (Ca2+) occurs. The Ca2+ activates the enzyme phospho-
lipase C (PLC) to produce inositol 1, 3, 5 triphosphate (IP3) and diacyl-
glycerol (DAG) from phosphatidyl 1, 3 bisphosphate (PIP2). The IP3
molecule binds to the protein receptor on the endoplasmic reticulum
(ER) to promote a release of Ca2+ from the ER. This subsequently in-
crease in cytoplasmic Ca2+ promotes exocytosis of the pre-packaged ma-
ture insulin and active C-peptide, which are released into circulation.
GLUT2: Glucose transporter 2; Glucokinase (GCK) encoded by GCK
gene; ADP: Adenosine diphosphate; ATP: Adenosine triphosphate;
Monocarboxylate transporter (MCT1) encoded by SLC16A1 gene;
Glutamate dehydrogenase (GDH) encoded by GLUD1 gene;
Uncoupling protein 2 (UCP2) encoded by UCP2 gene; L-3-
hydroxyacyl-coenzyme A dehydrogenase (HADH) encoded by HADH
gene; SUR1 subunit of the KATP channel encoded by the ABCC8 gene;
Kir6.2 subunit of the KATP channel encoded by KCNJ11 gene;
Hepatocyte nuclear factor 4α (HNF4α) encoded by HNF4A gene;
Hepatocyte nuclear factor 1α (HNF1α) encoded by HNF1A gene;
HK1: Hexokinase 1 encoded by the gene HK1; CACNA1D: calcium
voltage-gated channel subunit alpha1 D. Mutations in Forkhead Box
Protein A2 (FOXA2), Phosphoglucomutase 1 (PGM1) and
Phosphomannomutase 2 (PMM2) are not included in the cartoon.
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inhibition byGTP andATP [28]. This loss of regulation leads to
an increase in the activity of GDH, a subsequent increase in the
amount of α-ketoglutarate entering the TCA cycle and conse-
quently an unregulated insulin secretory response.
Individuals with GLUD1 variants usually present with a
milder form of HH that is often diagnosed outside of the neo-
natal period and is diazoxide-responsive [27]. In some patients
dietary protein restriction may also be required. A consistent
feature of this disorder is the presence of plasma ammonium
concentrations raised two to three times the upper limit of
normal. The presence of persistent hyperammonemia, in most
but not all patients with GLUD1 variants [29], has led to this
subtype of hyperinsul inism being referred to as
Hyperinsulinism/Hyperammonemia (HI/HA) syndrome
(OMIM #606762). An increased risk of epilepsy has also been
observed in individuals with disease-causingGLUD1 variants
[29].
In the majority of cases GLUD1 variants arise de novo,
with no family history of hyperinsulinism. In keeping with
their dominant nature, 50% of future offspring of affected
individuals are at risk of inheriting the variant and developing
HH.
Glucokinase (GCK) Within the pancreatic β-cell glucokinase
(GCK) plays a key role in linking insulin secretion to a glucose
challenge by facilitating the phosphorylation of glucose to
glucose-6-phosphate, the first step in glycolysis.
Heterozygous gain-of-function variants in GCK cause HH
by increasing the affinity of GCK for glucose which then acts
to lower the threshold for glucose-stimulated insulin secretion
[30] (OMIM #602485).
Individuals with gain-of-function GCK variants will often
have a dominant family history of HH. The absence of a fam-
ily history should however not preclude testing as de novo
variants have been reported [31]. Variability in the severity
of HH is also observed both in terms of age at presentation,
which can range from birth to adulthood, and treatment re-
sponse [31, 32]. Whilst the majority of individuals are suc-
cessfully treated with diazoxide, some patients have medically
unresponsive HH and require near-total pancreatectomy [32].
Although these differences in phenotype are likely to correlate
with the functional severity of the variant, phenotypic variabil-
ity within families with the same variant has been observed
and is likely to be a consequence of genetic background and/
or environmental factors [33].
Hydroxyacyl-coenzyme a dehydrogenase (HADH) HADH en-
codes 3-Hydroxyacyl-coenzyme A dehydrogenase, an
intramitochondrial enzyme that catalyzes the penultimate re-
action in the β-oxidation pathway. Loss-of-function variants
in HADH result in loss of interaction between HADH and
glutamate dehydrogenase [34, 35]. This in turn leads to an
increase in glutamate dehydrogenase activity, a subsequent
rise in intracellular ATP and upregulated insulin secretion
[36].
Patients with HADH disease-causing variants present with
diazoxide-responsive protein-induced HH [36–38](OMIM
#609975). The severity in phenotype ranges from mild late
onset hypoglycemia to severe neonatal hypoglycemia. In
some patients there are raised plasma concentrations of 3-
hydroxybutyrylcarnitine and urinary 3-hydroxyglutaric acid
[36]. Loss- of- function variants in HADH are recessively
inherited and this is the most common genetic subtype of
HH in consanguineous individuals [39].
Hepatocyte nuclear factors (HNF4A and HNF1A) The hepato-
cyte nuclear transcription factors, HNF1A and HNF4A, play
crucial roles in glucose-stimulated insulin secretion as evi-
denced by the identification of loss-of- function variants in
these genes in individuals with maturity-onset diabetes of
the young (MODY)(OMIM #125850), an autosomal domi-
nant form of diabetes typically diagnosed before the age of
25 years [40]. HNF4A variants were reported to cause a bi-
phasic phenotype in individuals presenting with macrosomia
and transient HH during the neonatal period and diabetes in
later life [41]. The duration of HH varies markedly with some
patients treated with intravenous glucose infusion for 1–
2 days, yet others require diazoxide treatment for up to
11 years [42–44]. HH with Fanconi syndrome, a renal tubular
dysfunction, has been reported in at least 8 patients with
HNF4AHH, all individuals have the p.R76W variant suggest-
ing that this is a mutation specific phenotype [45–48]. A few
cases with HNF1A variants and transitory neonatal hypogly-
cemia have also been reported [45, 49].
Whilst a dominant family history of macrosomia, neonatal
hypoglycemia and/or young onset diabetes can help to guide
genetic testing for this condition, the absence of affected fam-
ily members should not preclude analysis of HNF4A as de
novo disease-causing variants have been reported [43].
Solute carrier family 16 member 1 (SLC16A1) SLC16A1 gene
encodes the monocarboxylate transporter (MCT1) which
transports the insulin secretagogues pyruvate and lactate.
Under normal physiological conditions SLC16A1 is not
expressed in the β-cell thus preventing insulin from being
secreted in response to lactate and pyruvate. Rare activating
dominant variants result in the expression of MCT1 in the β-
cell leading to pyruvate-stimulated insulin secretion following
exercise [50, 51] (OMIM #610021). For patients with
exercise-induced HH, treatment is not usually necessary as
hypoglycemic episodes may be prevented by avoiding stren-
uous exercise [52].
Uncoupling protein 2 (UCP2) UCP2 gene encodes an inner
mitochondrial carrier protein UCP2which is widely expressed
in tissues, including pancreatic islets [53, 54]. UCP2 can
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inhibit ATP generation by causing proton leak across the inner
mitochondrial membrane and negatively regulates glucose-
mediated insulin secretion [54]. Inactivating heterozygous
mutations in the UCP2 gene can enhance glucose oxidation
and increase intracellular ATP synthesis leading to HH [54].
UCP2 mutations can present with either transient or
prolonged HH [55]. However, in a recent published study,
no mutations were detected in the UCP2 gene among 206
diazoxide responsive patients [56], suggesting that the role
of UCP2 in HH needs further investigation.
Hexokinase 1 (HK1) HK1 encodes the hexokinase HK1, which
catalyzes the phosphorylation of glucose to glucose-6-phosphate
as substrate for glycolysis. A family with dominant gain-of-
function mutation in the HK1 gene has been reported with “idi-
opathic hypoglycemia of infancy” [57]. In vitro studies evaluat-
ing pancreatic β-cells from CHH patients have shown inappro-
priate expression of HK1. These pancreatic tissues showed func-
tional KATP channels with inappropriate secretion of insulin at
low plasma glucose concentrations (1 mmol/L) [58].
Phosphoglucomutase 1 (PGM1) PGM1 is involved in glyco-
genmetabolism and is responsible for reversible conversion of
glucose-6-phosphate to glucose-1-phosphate. PGM1 gene en-
codes the enzyme PGM1 and recessive loss-of-function mu-
tations in PGM1 cause hypoglycemia [59].
Children with PGM1mutation presented with postprandial
HH and fasting hyperketotic hypoglycemia [59].
Phosphomannomutase 2 (PMM2) Recessively inherited vari-
ants in PMM2, which encodes a key enzyme in N-glycosyla-
tion, have been identified in individuals with HH and poly-
cystic kidney disease. In all individuals a c.-167G > T
promotor variant was identified that was either homozygous
or in trans with a coding variant [60].
The majority of patients with PMM2 variants present with
macrosomia at birth and hypoglycemia in the first year of life.
For many, hypoglycemia was the presenting feature and often
manifested with seizures. Patients are responsive to treatment
with diazoxide [60].
Forkhead box protein A2 (FOXA2) Mutations in FOXA2 have
been reported to cause hypopituitarism, CHH and endoderm-
derived organ abnormalities. These children have a unique
clinical phenotype of hypopituitarism, CHH, dysmorphic fea-
tures, and liver, pancreas, heart and gastrointestinal abnormal-
ities [61, 62].
Calcium voltage-gated channel subunit alpha1 D (CACNA1D)
CACNA1D gene encodes an L-type voltage-gated calcium
channel which is expressed in pancreatic β-cells and regulates
insulin secretion. Mutations in CACNA1D have been reported
to cause HH, heart defects and severe hypotonia [63].
Eukaryotic translation initiation factor 2 subunit 3 (EIF2S3)
Three cases published with variant in EIF2S3 present an un-
usual dysregulation of glucose fluctuating between diazoxide-
responsive HH and postprandial hyperglycemia, along with
learning difficulties and hypopituitarism [64].
4.3 Other forms
4.3.1 Postprandial forms of HH
In postprandial hyperinsulinemic hypoglycemia (PPHH), hy-
poglycemia is induced hours after meal intake due to
inappropriate/exaggerated insulin secretion in response to
the meal. The most common cause is “dumping” syndrome
in infants /chi ldren who have undergone Nissen
fundoplication/gastric bypass [65, 66]. Children with PPHH
after Nissen fundoplication have an abnormally exaggerated
secretion of the insulin secretagogue glucagon-like peptide 1
(GLP-1) which may contribute to the exaggerated insulin
surge and resultant hypoglycemia [67].
PPHH is also reported in the insulin autoimmune syndrome
leading to development of insulin binding autoantibodies in chil-
dren whowere not previously exposed to exogenous insulin [68].
4.3.2 Other causes of HH
Insulinoma is a rare cause of hyperinsulinism and must be
considered in older children or adolescents presenting with
HH [69]. A detailed family history of tumors especially like
insulinoma, is relevant as it can be part of multiple endocrine
neoplasia syndrome type 1 (MEN1).
Munchausen by proxy leading to exogenous administration
of insulin or anti-diabetic drugs such as sulphonylureas can
present as factitious HH. This has led to misdiagnosis and
consequent pancreatectomy [70].
4.3.3 Syndromes associated with HH
A large number of syndromes are associated with HH, with
Beckwith-Wiedemann syndrome (BWS) being one of the
commonest [71]. Table 2 lists the syndromic associations with
HH, although the exact mechanism for HH is still not well
understood in all the conditions. Most syndromic forms are
diazoxide-reponsive and HH resolves overtime.
5 Pathophysiology of HH - histological
subtypes
There are three histological forms of CHH (Fig. 2); Focal form
(F-CHH), Diffuse form (D-CHH) and atypical. The clinical
presentation appears to be similar, although their molecular
mechanisms are quite different. In most cases D-CHH is
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inherited in an autosomal recessive manner whereas the F-
CHH is sporadic [22, 72].
5.1 Focal form of CHH (F-CHH)
Focal lesions occur when the abnormal pancreatic β-
cells are localized to a single specific location in the
pancreas. They are the result of two unique events, first
the inheritance of a paternally inherited ABCC8 or
KCNJ11 mutation at 11p15.1, and secondly the loss of
the corresponding maternal allele within the focal le-
sion. This causes an imbalance in the expression of
imprinted genes such as the maternally expressed tumor
suppressor gene H19 and CDKN1C, and the paternally
expressed growth factor IGF-2, at 11p15.5 [73] leading
to β-cell hyperplasia. Within the focal islet cell lesion
there is adenomatous hyperplasia and abnormally large
nuclei in the affected cells.
A duplication of the paternal allele located on chro-
mosome 11 has also been found in some patients with
F-CHH [74]. Outside the lesion, normal endocrine tissue
with small nuclei exists. These cells appear to have less
cytoplasm and diminished proinsulin production
[75–78].
Table 2 Syndromic forms of HH
- Various developmental syn-
dromes have been described with
the gene/s linked to the condition
and the common clinical features
[203]
SYNDROME NAME GENETIC ETIOLOGY
gene (location)
CLINICAL CHARACTERISTICS
Pre- and postnatal overgrowth (Macrosomia)
Beckwith-Wiedemann (11p15) Macroglossia, abdominal wall defects, ear lobe
pits/ creases, hemihypertrophy, tumor risk
Sotos NSD1 (5q35) Macrocephaly, frontal bossing, pointed chin,
developmental delay, tumor risk
Simpson-Golabi-Behmel GPC3 (Xq26),
GPC4 (Xp22)
Coarse facial features, broad feet, polydactyly,
cryptorchidism, hepatomegaly, tumor risk
Perlman DIS3L2 (2q37) Inverted V-shaped upper lip, prominent forehead,
developmental delay, hypotonia, tumor risk
Postnatal growth failure (short stature)
Kabuki KMT2D (12q13),
KDM6A (Xp11.3)
Arched eyebrows, long eyelashes, developmental
delay, fetal finger pads, scoliosis, heart defects,
hypotonia
Costello HRAS (11p15) Deep palmar/plantar creases, developmental delay
coarse facial features, heart abnormalities,
papillomas, tumor risk
Chromosomal abnormality
Mosaic Turner (Loss of X in some cells) Milder Turner syndrome phenotype (short stature,
coarctation of aorta, gonadal dysgenesis)
Patau Trisomy 13 Developmental delay, microphthalmia, heart
& neural defects
Congenital disorders
of glycosylation
Types 1a, 1b, and 1d PMM2 (16p13.2),
MPI (15q24.1),
ALG3 (3q27.1)
Developmental delay, hypotonia, growth failure
Contiguous gene deletion affecting the ABCC8 gene
Usher 11 genes Hearing loss, visual impairment
Abnormalities in calcium homoeostasis
Timothy CACNA1C (12p13.33) Long QT syndrome, syndactyly,
developmental delay, immune deficiency
Insulin receptor mutation:
Insulin resistance
syndrome
(leprechaunism)
INS (19p13) Hypo- and hyperglycemia, pre- and postnatal
growth restriction, elfin-like features, hirsutism
Other Syndromes:
Congenital central
hypoventilation
syndrome
PHOX2B (4p13) Central hypoventilation, “box-shaped” face,
neurocristopathies
(Hirschsprung disease, tumor risk)
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Patients who have a heterozygous paternally inherited mu-
tation in ABCC8 or KCNJ11 could have F-CHH, which ac-
counts for 30–40% of all CHH cases [79]. F-CHH is con-
firmed by a fluorine-18 dihydroxyphenylalanine-positron
emission tomography (18F-DOPA-PET) scan, which can
show the presence of a focal lesion and determine its location
with diagnostic accuracy [80].
5.2 Diffuse form of CHH (D-CHH)
The D-CHH form occurs when all the islet cells in the pan-
creas are abnormal [77, 81]. Patients with a homozygous re-
cessive or a compound heterozygote mutation in ABCC8 or
KCNJ11 present with D-CHH. These patients are usually
medically unresponsive, and this histological form accounts
for 60–70% of all CHH cases. Most islets throughout the
entire pancreas are affected with the presence of large
hyperchromatic nuclei [75–78, 81].
5.3 Atypical forms of HH
Histologically atypical forms of CHH are categorized when
the pancreatic morphology does not fit into the F-CHH or D-
CHH types and are a mosaic pattern of the two [73, 82]. The
islets can either be enlarged or shrunken. Some cases have
been cured with a lesionectomy whilst others also require
medical management. However, to date only one patient has
been described with a ABCC8 nonsense mutation (Q54X)
causing this histological form of CHH [82]. Studies have
shown that the heterogeneous expression of β-cells HK1 in
the atypical CHHmay be causing the abnormal insulin release
[83, 84].
6 Clinical presentation of HH
HH usually manifests in infancy or early childhood, although
some patients can present during adolescence or adulthood.
Signs and symptoms of hypoglycemia are non-specific during
the neonatal period (poor feeding, jitteriness, irritability), chal-
lenging its diagnosis. At later ages, symptoms can be easier to
recognize and can be classified as adrenergic (hunger, pallor,
tachycardia, tremor, diaphoresis) and neuroglycopenic (tired-
ness, blurred vision, confusion, coma and even death).
Risk factors for HH need to be looked for in the perinatal
history. These include maternal intrapartum administration of
hypoglycemic agents, stressful delivery, large/low birth
weight, and neonatal polycythemia or jaundice, among others.
Examination of the baby will search for macrosomia/leanness,
careful phenotypic characterization to identify syndromes,
features of cardiomyopathy (due to glycogen storage in
HH), hepatomegaly present in metabolic conditions (also
present in HH), and midline abnormalities (including genita-
lia) to exclude hypothalamic-pituitary deficits. Data in the
family history could suggest a genetic inheritance, therefore
anamnesis must enquire for consanguinity, cases of diabetes
mellitus, hypoglycemia, seizures and unexplained deaths [85].
7 Diagnostic investigations of HH
Any child requiring intravenous glucose load greater than
8 mg/kg/min (normal requirement is 4-6 mg/kg/min) to avoid
hypoglycemia, can essentially be labeled as HH [86]. The
timing of hypoglycemic events with regard to meals will give
insight into the intrinsic mechanism. HH typically manifests
during brief periods of fasting, however certain types can be
manifest soon after meal ingestion (protein induced HH) or
Fig. 2 Diffuse and focal form of
HH with 18F-DOPA-PET-CT
images. A – Diagrammatic repre-
sentation of diffuse form of CHH
and B – 18F-DOPA-PET image
of diffuse form of CHH. C –
Diagrammatic representation of
focal form of CHH (showing dif-
ferent types of focal lesions) and
D – 18F-DOPA-PET-CT image of
focal lesion in the head of pan-
creas. SUV – Standardized uptake
value.
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hours after meal ingestion (postprandial HH). Should there be
a clear link between physical activity and occurrence of hypo-
glycemia, then exercise induced HH should be excluded.
7.1 Biochemistry
Biochemical interpretation will only be possible if the critical
sample is taken adequately at the time of hypoglycemia
(≤3.0 mmol/l), ideally in a controlled fasting setting. HH will
demonstrate detectable C-peptide or insulin in the face of hy-
poglycemia, with simultaneously low/undetectable alternative
substrates (ketones and fatty acids) [86, 87]. Of note, the con-
centration of insulin does not parallel the degree of severity of
the condition [88, 89]. Table 3 defines the diagnostic criteria
for HH. If a particular mechanism is suspected to trigger HH
(exercise, protein, carbohydrate etc) specific stimulation tests
will be carried out:
7.1.1 Protein load test
In this test leucine or a combination of aminoacids is admin-
istered enterally. Evidence of raised insulin concentrations at
the time of hypoglycemia will confirm the clinical suspicion
of protein sensitive HH [29].
7.1.2 Oral glucose tolerance test / mixed meal test
Enteral administration of a mixed meal or oral glucose load
followed by hypoglycemia with a detectable insulin within 2–
5 h, indicates incretin mediation leading to postprandial HH.
In adults the prefered test is the standardized hyperglucidic
breakfast [91], which has not yet been standardized in
children.
7.1.3 Exercise test and pyruvate load
Biochemical evidence of HH during these tests indicate a
lactate/pyruvate mechanism triggering exercise induced HH
[92].
7.1.4 Fructose load test
Individuals with ketotic hypoglycemia after fructose ingestion
should undertake a fructose load test to identify hereditary
fructose intolerance and fructose-1,6-diphosphatase
deficiency, and this can be followed by genetic testing.
7.1.5 The role of real-time continuous glucose monitoring
(CGM)
CGM measures interstitial glucose concentrations indicating
the direction, magnitude, frequency, duration and causes of
fluctuations in these. There is now a study on its accuracy in
children with HH [93], as this can significantly improve the
quality of life of these patients.
7.2 Imaging
7.2.1 Recent advances in diagnostic imaging of HH
As is not possible to differentiate between F-CHH and D-
CHH based on clinical presentation and biochemical features,
Table 3 Diagnostic criteria for
HH - The cut-off values for each
analyte to aid in the diagnosis of
HH. IGFBP-1: Insulin growth
factor binding protein-1. HI/HA:
Hyperinsulinemic hypoglycemia
hyperammonemia syndrome.
HADH: short chain L-3-
hydroxyacil-CoA dehydrogenase.
Im: intramuscular. Iv: intrave-
nous. Sc: subcutaneous *[90, 200,
203]¥
Serum analyte Result in patients with HH
Blood glucose < 3.0 mmol/l (54 mg/dl) and:
Insulin Detectable
C-peptide Detectable (≥0.5 ng/mL¥)
Free fatty acids Low or suppressed (<1.5 mmol/l* or < 1.7 mmol/l¥)
Ketone bodies Low or suppressed (3-β-hydroxybutyrate <2 mmol/l* or < 1.8 mmol/l¥)
IGFBP-1 Low (≤110 ng/mL¥) as insulin negatively regulates IGFBP-1 expression
Ammonia Normal. Can be raised in HI/HA syndrome
Hydroxybutyrylcarnitine Normal. Raised in HH due to HADH mutation
Cortisol, Growth
hormone
Raised. Generally Cortisol >20 μg/dL [500 nmol/L]; growth hormone
>7 ng/mL - younger children might have poor counter-regulatory response
Amino acids and urine
organic acids
Normal. Leucine, isoleucine and valine may be suppressed in HH
Proinsulin >20 pmol/l
Additional information when diagnosis of HH uncertain:
Glucose infusion rate >8 mg/kg/min to achieve euglycemia
Im or iv glucagon
administration or
sc octreotide administration
>1.5 mmol/L or 27 mg/dl (Positive glycemic response)
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pre-operative differentiation of both subtypes is critically im-
portant. Conventional radiological imaging such as Magnetic
Resonance Imaging (MRI) and Computerized Tomography
(CT) scans fail to localize the focal lesions. Genetic analysis
for mutations inABCC8/KCNJ11, with combination of recent-
ly described Fluorine 18 L-3, 4- dihydroxyphenyalanine pos-
itron emission tomography (18F-DOPA-PET-CT) scanning,
allows differentiation between F-CHH and D-CHH with a
high sensitivity (88%) and specificity (94%) [94–98], with
an accuracy of 100% [99–102]. The principle of 18F-
DOPA-PET analysis is based on the selective uptake of L-
DOPA by β-cells and its conversion into dopamine by
DOPA decarboxylase enzyme, which is expressed in the pan-
creatic β-cells. Thus, imaging with 18F-DOPA-PET-CT
should be performed in all patients who are thought to have
F-CHH. Some patients have been described with atypical his-
tological forms, which are either atypical focal, atypical dif-
fuse or ectopic β-cell hyperplasia and do not show classical
features of F-CHH or D-CHH [103]. Demonstration of in-
creased activity of DOPA decarboxylase by 18F-DOPA-PET
in combination with an enhanced CT imaging can successful-
ly differentiate diffuse and focalβ-cell hyperplasia. Therefore,
this technique has radically changed the surgical approach to
patients with medically unresponsive HH [102, 104].
A dosimetry study of 18F-DOPA derived from the PET-CT
images in ten infants (median age 4.84 weeks) with HH sug-
gested that a modest radiation dose (0.30 ± 0.04 mSv/MBq)
was adequate [105]. However, there have been recent reports
of its inaccuracy in precisely detecting focal lesions [106,
107]. Glucagon-like-peptide-1 (GLP-1) receptor analogs are
the latest agents being used in the detection of insulinomas in
adults [108, 109]. Similarly, this isotope is being investigated
in children to detect focal lesions.
7.2.2 Imaging for insulinoma
Most insulinomas are benign (islet-cell tumors) and usually
very small (<2 cm) making it difficult to localize with the
current imaging techniques. Various non-invasive techniques
have been used for the detection of insulinomas e.g.,
transabdominal ultrasonography, spiral CT, MRI, 111In-
pentetreotide imaging, and 18F-l-dihydroxyphenylalanine
PET. In difficult cases, invasive procedures like endoscopic
ultrasonography or selective arterial calcium stimulation test
with hepatic venous sampling have also been used [110].
A systematic review and meta-analysis of (68)Ga-
DOTATATE compared with octreotide and conventional
imaging documented a high sensitivity (90.9%) and speci-
ficity (90.6%) of (68)Ga-DOTATATE in detecting neuro-
endocrine tumors [111]. Various Gallium based isotopes
have also been used to detect insulinoma in adults [108,
112].
8 Management of HH
Maintaining normoglycemia (blood glucose >3.5 mmol/l) is
paramount to avoid hypoglycemic brain injury in view of the
hypoketotic nature of HH [113]. This may be achieved by
increasing glucose administration (feeds or intravenous (iv)
fluids), stimulating endogenous glucose release (glucagon ad-
ministration) or suppressing insulin release from the β-cell
(diazoxide, octreotide, nifedipine). Oral feeds with additional
glucose polymer in combination with iv fluids can also be
used to maintain normoglycemia. The traditional and new
drugs available for the management of HH are summarized
in Table 4.
9 Current medical management
9.1 Acute management of hypoglycemia
If the oral route is unavailable or glycemia is not improving
despite oral glucose (glucose gel/glucose containing drinks or
tablets), then an iv dextrose bolus (2 ml/kg 10%Glucose)
needs to be administered followed by continuous iv glucose
infusion (>8 mg/kg/min). If there is persistence of hypoglyce-
mia, hypoglycemic seizure or inadequate iv access, then an
intramuscular or subcutaneous bolus (1 mg) or infusion of
glucagon can be life saving as it causes immediate release of
glycogen stores from the liver leading to a temporary im-
provement in blood glucose concentrations. [117].
As high iv glucose concentration is usually needed for
weeks, insertion of a central venous access supports in man-
aging glycemia safely.
9.2 Long-term pharmacological agents
Medical therapies can be tried to wean the infant off iv support
and achieve a near-normal feeding pattern. Surgical therapy is
considered when trial of medical therapies is unsuccessful or
in case of established F-CHH.
HH drug responsiveness is defined by: 1) normal feeding
frequency and volume, 2) fasting capability adequate for age
whilst maintaining euglycemia, 3) low/suppressed serum in-
sulin level at the end of the fast, and 4) appropriate generation
of ketone bodies and fatty acids by the end of the fast [117].
Diazoxide The first drug of choice is diazoxide [86], which
requires a functional KATP channel to bind onto and is hence
ineffective in D-CHH due to an inactivating KATP mutation
and in most cases of F-CHH. Most other forms of HH and
protracted HH secondary to risk factors such as IUGR and
perinatal asphyxia respond to treatment with diazoxide. Due
to its fluid retaining properties, diazoxide therapy must be
used with caution in infants with HH who are often receiving
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large volumes of iv/oral fluids to maintain normoglycemia.
Fluid restriction prior to starting diazoxide is commonly prac-
ticed, along with concomitant use of a thiazide diuretic such as
chlorothiazide, which also has a synergistic action over the
KATP channels.
9.2.1 Medical management of diazoxide unresponsive D-CHH
NifedipineAuthors suggest triyng it before heading to pancre-
atectomy [118] as there have been isolated case reports on
successful treatment of HH with nifedipine [119–121] but
experience of large HH centers has generally been disappoint-
ing [117, 122, 123]. It is sometimes considered as an add-on
drug in partial diazoxide/octreotide resistance, and/or
following partial pancreatectomy [122, 124] but rarely used
as monotherapy.
Octreotide Octreotide is a second-line treatment for
diazoxide-insensitive patients [125, 126]. It may be used
in combination with diazoxide and glucagon in cases with
partial diazoxide response, or often combined with fre-
quent feeding which may require a gastrostomy to enable
high calorie bolus feeding during the day and overnight
continuous feeds. As octreotide binds to the somatostatin
receptors SSTR-2 and SSTR-5, prolonged use may devel-
op into drug desensitizing caused by internalisation of the
receptors [122].
Table 4 Standard and novel drugs used in the management of HH - Medications used for the treatment of HH, along with their dose, mechanism of
action and side effects [114–116, 134, 140, 201]
Medication
(route of administration)
Total daily dose Action mechanism Side effects
Standard drugs Diazoxide
(enteral)
5-20 mg/kg/day
(divided in 3 doses)
Binds to the SUR1 subunit of intact
KATP channels, opening the
channel and inhibiting insulin
release
Common: Fluid and sodium retention,
hypertrichosis, anorexia.
Rare: Cardiac failure, pulmonary
hypertension**, blood dyscrasia,
hyperuricemia, paradoxical
hypoglycemia
Chlorothiazide
(enteral)
7-10 mg/kg/day
(divided in 2 doses)
Synergy with diazoxide over KATP
channels inhibiting insulin
secretion. Prevents fluid overload
Hyponatremia, hypokalemia
Glucagon
(sc/im bolus;
sc/iv infusion)
Bolus: 0.02 mg/kg/dose
Infusion: 2.5–10 mcg/kg/h
Stimulates glycogenolysis,
gluconeogenesis, ketogenesis,
lipolysis
Skin rash, vomiting. Paradoxical
rebound hipoglycemia if dose
>20mcg/kg/h (high dose stimulates
insulin release)
Octreotide
(sc)
5–40 mcg/kg/day
(divided in 3–4 doses
or continuous infusion)
Activation of SSTR-2 and SSTR-5.
Stabilisation of KATP channel, re-
duces calcium entry in β-cell, in-
hibition of insulin secretion.
Inhibitition of INS promoter.
Acute: Abdominal discomfort,
vomiting, diarrhea, anorexia,
hepatitis, transaminasemia, long QT
syndrome, necrotizing enterocolitis,
tachyphylaxis.
Long-term: Cholelithiasis, intestinal
hypomobility, suppression of GH
and TSH
Nifedipine
(enteral)
0.25–2.5 mg/kg/day
(divided in 2–3 doses)
Blockage of β-cell calcium channel
activity, leading to inhibition of
insulin exocytosis
Hypotension
Acarbose (enteral) 6.25–300 mg/day (divided
in 3 doses – before main
meals)
Inhibits intestinal α-glucosidase
(cleaves polysaccharides to
monosaccharides)
Intestinal discomfort, diarrhoea,
flatulence, raised transaminases
Novel drugs Lanreotide and
long-acting
octreotide
(deep sc or im)
30–60 (max 120*) mg/dose
(every 4 weeks)
Like octreotide. High affinity for
SSTR 2 & 5, and reduced affinity
for SSTR 1, 3 & 4
Same as octreotide. Pain at injection
site. No long-term data available yet.
mTOR inhibitors
(enteral)
Starting dose: 1 mg/m2/day
(divided in 2 doses).
Adjust dose aiming for
blood concentrations
5-15 ng/ml
Inhibits mTOR complex 1. Inhibits
β-cell proliferation and insulin
secretion. Posible induction of
peripheral insulin resistance
Immune suppression, hyperlipidemia,
hypertransaminasemia, mucositis,
thrombocytosis
Sc: subcutaneous. Im: intramuscular. Iv: intravenous. SSTR: Somatostatin receptor. INS: insulin gene. SUR1 = sulfonylurea receptor 1. KATP =ATP-
sensitive potassium channel.
**[115, 116]
*90-120 mg every 4 weeks [134]. The starting dose of Lanreotide autogel 30 mg has been found to be effective [132, 133]
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Glucagon Iv or subcutaneous (sc) glucagon [127] may be
helpful during the initial stabilization period and before sur-
gery. However, this treatment has not been of long-term ben-
efit. It can also be administered (alone or in combination with
Octreotide) to stabilize blood glucose concentrations in the
acute management and prevent near-total pancreatectomy in
infants with HH [128]. Continuous sc glucagon infusion can
frequently complicate by catheter obstructions occurring daily
or 2–3 times per week [128].
Acarbose For postprandial HH the first approach is diet mod-
ification. This includes: frequent feeds of long-acting carbo-
hydrates, abundant protein and supplements of fibre and fat
emulsions [129]. If hypoglycemia persists, acarbose is the
preferred medical option as it slows the absorption of glucose
into the blood stream, thus avoiding a glycemic peak followed
by insulin release [130].
10 Novel medical therapies
10.1 Long-acting somatostatin analogues
Lanreotide and Long-acting release octreotide (LAR-
Octreotide) are two formulations used in few numbers of pa-
tients with HH [131–136] reported not only to be useful in the
management of HH in children, but potentially displaying a
more stable glycemic control than octreotide [134].
Lanreotide has also been proven useful in managing inopera-
ble F-CHH [137].
10.2 mTOR inhibitors
The intracellular mTOR pathway is involved in β-cell growth
and altered insulin secretion in patients with insulinoma [138].
Therefore, mTOR inhibitors such as sirolimus (formerly
known as rapamycin) and everolimus have been used to treat
this tumor. Although the exact mechanism of sirolimus in HH
still needs to be elucidated, it has been hypothesized that the
mTOR complex 1 may be overactivated in D-CHH [139]. The
first study reported the use of sirolimus in 4 children with
severe D-CHH who achieved glycemic control avoiding pan-
createctomy and with no major side effects [140]. This has
been followed by various case reports of HH in children of
various ages who have benefitted from sirolimus [141–145].
However, there have been reports about its severe side effects
as well as poor response in others [146–149]. Our center has
tried sirolimus on 22 patients with various forms of HH, out of
which 21 showed glycemic response, however 19 patients
developed side effects, recurrent and frequent infections being
the most common infections [150]. There is no clear correla-
tion between genetic etiology and response to sirolimus.
11 Potential novel therapies – The future
11.1 GLP-1 antagonists
GLP-1 acts on the β-cell promoting its proliferation and stim-
ulating insulin release [151]. Mouse models with KATP chan-
nel defects leading to HH, significantly improved their glu-
cose concentrations when treated with GLP-1 receptor antag-
onist (exendin-9-39) [152]. Infusion of exendin-9-39 has been
tried in 9 adult patients with HH due to KATP mutations [153],
where all patients demonstrated increased fasting mean glu-
cose and glucose area under the curve, raising expectation for
its near-future use in children with this condition.
11.2 Pharmacological trafficking chaperones
Some mutations in the ABCC8 gene prevent trafficking of
parts of the SUR1 channel from the endoplasmic reticulum
to the surface of the cell. Carbamazepine [154] and sulfonyl-
ureas [155] – glibenclamide and tolbutamide - are KATP chan-
nel inhibitors and chaperones that have proven to amend chan-
nel trafficking defects in many ABCC8mutations by allowing
intersubunit interactions between SUR1 and Kir6.2 [156].
This has been now confirmed in mouse functional studies as
well [157] reinforcing its potential for clinical use.
11.3 Glucagon – New formulations and delivery
Subcutaneous glucagon infusion via pump has been used as
long-term treatment for HH patients at home [158]. Practical
issues with its administration remain unsolved as it can cause
mechanical obstruction due to its formulation. However, a
stable form of glucagon formulation could be a potential use-
ful tool that is being explored [159, 160].
12 Surgical management
12.1 Surgery for F-CHH
Removal of the affected part of the pancreas achieving com-
plete cure is the surgical aim for the F-CHH. A multidisciplin-
ary team (endocrinology, radiology, and histopathology)
should be involved in managing patients with F-CHH and
D-CHH [161, 162]. In most cases, pre-operative 18F-DOPA
PET-CT helps exact localization of the focal lesion and aids
the surgeon. Intra-operative biopsies are important to ensure
complete excision with histological confirmation of clear mar-
gins. Laparoscopic lesionectomy is the preferred surgical ap-
proach when the focal lesion is easily accessible (i.e. body or
tail of pancreas) offering the benefit of shorter post-operative
care [163]. Focal lesions that are difficult to access such as in
the head of the pancreas usually require open laparotomy for
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resection of most of the pancreatic head and Roux-en-Y
pancreaticojejunostomy [164].
12.2 Surgery for D-CHH
Near-total pancreatectomy (95–98% of the pancreas), the only
option for medically unresponsive D-CHH has largely been
reported to have unsatisfactory outcomes [165, 166]. In a large
study, nearly 59% of patients that underwent near total pan-
createctomy continued to experience hypoglycemia, though it
was usually easier to manage with dietetic/medical therapy.
Post-operatively, hyperglycemia was common as well with
increasing incidence as age progressed and a 100% incidence
by 13 years of age [166]. Complex glucose derangements with
persisting fasting hypoglycemia and post-prandial hypergly-
cemia were also reported in 35% of patients. Exocrine pancre-
atic insufficiency is also common following near-total pancre-
atectomy for D-CHH [166]. Laparoscopic surgery is now the
preferred option as opposed to the traditional open approach
[161, 167].
12.3 Surgery for insulinoma
Surgical removal of the tumor is the mainstay therapy for
childhood and adult insulinoma, and its overall cure rate is
up to 98% [168, 169]. Prognosis depends on the tumor stage
at the time of presentation and success rate of complete resec-
tion. The mode of surgery depends on the tumor size, locali-
zation, and metastatic characteristics [69, 170]. For small be-
nign tumors with no metastasis that are located at least 2–
3 mm from the main pancreatic duct, a limited enucleation
should be performed [171]. A tumor that is invading the pan-
creatic duct or great vessels with risk of malignancy and
lymph node invasion, and that is compressing the distal pan-
creatic duct, might require a more extensive surgical resection.
The surgical resection procedure depends on the site of the
insulinoma and includes mid-body pancreatectomy, distal
pancreatectomy, or pylorus-preserving Whipple procedure
[171, 172].
13 HH monitoring and follow up
Children with HH need regular monitoring of their blood glu-
cose at home. The follow-up of these children requires in-
volvement of a multidisciplinary team including pediatric en-
docrinologist, dietitian, nurse specialist, clinical psychologist,
developmental pediatrician and pediatric surgeon. Severity
and treatment requirement should be assessed periodically in
all children on medical therapy and the dose of medications
should be optimized based on their glucose monitoring and
fast tolerance test. It has been reported that for most patients
with KATP channel mutations who are managed by medical
treatment only, severity is reduced over time [173]. Children
need to be monitored for the side effects of the HH medica-
tions [135, 146, 147, 174, 175]. Also, the majority of children
with severe HH are on high carbohydrate feeds administered
via gastrostomy by bolus and/or continuous feeds, hence the
importance in receiving support from the community i.e. nurs-
ery, school, home etc. in these group of children. Post-surgical
patients require periodical monitoring including stool elastase,
capillary glucose measurements and oral glucose tolerance
test looking for complications (hypoglycemia, diabetes and
exocrine pancreatic insufficiency) [165, 166]. Various studies
evaluating the long-term outcome of patients with HH have
reported a high frequency of neurodevelopment delay and
various neurological disorders, including epilepsy and micro-
cephaly [5, 176, 177]. This group of children may need a
special education plan devised with the help of the educational
psychologist and developmental pediatrician.
14 Transition into adult service
Young adults with HH have complex management require-
ments that are best supported using a multidisciplinary ap-
proach [178]. The move from pediatric to adult services may
be a challenging time for adolescents transitioning to self-
management [179].
A transition service aims to bridge this changeover in care,
and support the adolescent [180] in terms of their health needs,
but also psychosocial development, including ability to
achieve independence and establish adult relationships [181,
182]. This specific age group are recognized to have barriers
that prevent optimal self-management, including [183];
& heightened concerns about peer relationships and social
interactions,
& frustration and fatigue from the management of a chronic
illness,
& incomplete knowledge and understanding of chronic dis-
ease management,
& inclination towards risk-taking and
& difficulties in the transition to self-management.
People with chronic conditions experience differences in
the clinical management approach of pediatric and adult care
settings during the transition process [182]. Pediatric teams
may overlook the growing independence of the individual,
however conversely, the encouragement to take responsibility
from adult care providers may lead to physical, psychological
and social development being neglected [182, 184, 185].
Consequently, young adults often feel misplaced in adult
services and this has been shown to lead to lower rates of
follow-up appointments, attendance and medication compli-
ance [181, 186].
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Discharge to a non-specialist adult team carries with it
some challenges, including lack of awareness about this rare
condition and its complex on-going health-needs. In addition,
non-specialist teams may not be best placed to undertake dis-
cussions around pre-conception counselling in those with a
confirmed genetic etiology.
14.1 Aims of the transition service
Recognizing the core attributes of this age group, a transition
service for patients with HH may be established, with the
following aims and in line with established NICE guidance
[178].
1. Supporting education: Establish and support under-
standing of HH. Where genetic causes are identified,
patients should be aware of this and have an understand-
ing of its inheritance.
2. Empowering self-management: To support handover
of care to the affected individual from the carers [187],
by encouraging shared decis ion-making and
empowering self-management, with an ultimate aim of
self-management [188].
3. Addressing parental and care-giver concern [189]:
Establishing an understanding between the young per-
son and their carer of how aspects of self-care might be
jointly undertaken and transferred is an important com-
ponent of managing distress, expectations and, ultimate-
ly, transition [190].
4. Addressing on-going medical issues: Table 5 summa-
rizes some of themedical issues that may be addressed in
a transition service. The risk and progression to diabetes
is variable and appropriate treatments for diabetes may
depend on both the mutation causing HH and the extent
of β-cell failure.
5. Dealing with impaired awareness of hypoglycemia
[191]: If found in severe cases of HH it can be formally
assessed using the validated Clarke [192] or Gold score
[193]. The evidence base for managing impaired aware-
ness of hypoglycemia is limited in the context of HH
[194] and so, care is needed in managing these individ-
uals. CGM could be of use in some cases [191].
6. Providing advice around driving: Supporting individ-
uals at high risk of hypoglycemia or impaired awareness
of hypoglycemia to apply for a driving license may be
explored, and fully explaining driving regulations in re-
lation to hypoglycemia is important for those starting to
learn to drive [195].
7. Providing support to higher educational institutions
and those in employment [196, 197]: Flexibility may
be required to allow time for testing, or additional breaks
for calorie consumption.
8. Pre-conception genetic counsel ing, where
appropriate: In those with confirmed dominant muta-
tions, ensuring adequate counseling around offspring,
and accessing genetic counselors when appropriate, is
important. Insulin modulates Sertoli cell function and
young hyperinsulinemic patients have been found to
have lower anti-Müllerian hormone and inhibin B se-
cretion [198]. This could therefore influence testicular
function and have a future impact on fertility, which still
needs to be studied.
9. Continued dietetic advice: On-going advice about die-
tary management of hypoglycemia, especially where
there is protein-induced hypoglycemia, and replacement
of calories with other macronutrients may be provided.
10. Alcohol and recreational drug advice [199]: alcohol
consumption can potentiate the risk of hypoglycemia
and also impair awareness of hypoglycemia.
Recreational drugs may also mask the adrenergic symp-
toms of hypoglycemia.
14.2 Developing the HH transition pathways
In line with NICE transition service guidelines [178], the op-
timal pathway for transitioning individuals with HH must be
developed, summarized in Fig. 3. This includes:
– Planning a service: Young people should be involved in
designing the service.
– Planning for transition, which should be appropriately
timed for the individual.
– Before Transition: young adults should have joint clinics
with the pediatric and adult teams.
15 Concluding remarks and future directions
HH is a challenging condition to treat due to its heterogeneity.
Despite diagnostic and therapeutic advances, HH remains an
important cause of morbidity in children, still accounting for
26–44% of permanent intellectual disabilities, especially in
neonatal-onset patients. The increasing use of NGS target
panels, combinedwith clinical, biochemical and imaging find-
ings allows differentiating the diagnostic management of chil-
dren with F-CHH, surgically curable, from those with D-
CHH, more conservatively treated with pharmacological and
nutritional interventions [200].
There is now more research of use of CGM in children
with HH which might help to detect early hypoglycemia
leading to prompt management [93]. There have been
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reports of pitfalls of 18F-DOPA PET-CT in accurately
detecting focal lesions in CHH [106, 173]. Glucagon-
like-peptide-1 (GLP-1) receptor analogs are the latest
agents being used in the detection of insulinomas in adults
[108, 109] and are similarly being trialed in children to
detect F-CHH.
Table 5 Summary of medical
issues encountered in adolescent
and young adult patients with
congenital hyperinsulinism and
the intervention required.
Medical Issue Support / Intervention needed
Confirmed mutation causing HH
Symptom control • Exploring precipitants
• Dietary interventions and advice
• Need for medical treatment e.g. diazoxide, calcium channel blockers,
somatostatin analogues.
• Accessing appropriate technology e.g. real-time CGM, where appropriate
Risk of diabetes • Aware of diabetes symptoms
• Annual glucose checks
• Understands the risk of diabetes
Managing diabetes in
non-pancreatectomized individ-
uals
• Establishing type of diabetes
• Impact of underlying genetic mutation
• Measuring endogenous insulin production to determine if insulin needed.
Managing diabetes in
pancreatectomized individuals
• Diagnosing and treating insulin-deficient diabetes in these individuals early
on
• Ensuring life-long insulin and clearly aware of diagnosis
• Managing concurrent exocrine failure
• Loss of glucagon may also contribute to problematic hypoglycemia
• Ensuring access to appropriate diabetes technologies e.g. insulin pumps and
continuous glucose monitoring
Impaired hypoglycemia awareness • Checking individuals know the symptoms of hypoglycemia
• Assessing awareness of hypoglycemia using validated scores e.g. Clarke or
GOLD score.
• Considering adjunctive use of monitoring technologies such as real-time
continuous glucose monitoring in those with hypoglycemia unawareness.
No mutation identified (in addition to above)
Exploring a genetic diagnosis • Ensuring panel of all genes tested
• Undertaking whole exome or whole genome sequencing studies to identify
novel genes
• Re-characterizing type of hyperinsulinism and considering alternative diag-
nosis
Counseling around diagnostic
uncertainty
• Ensure adequately knowledgeable about their condition
• Symptom control
• Need to continue medical therapy
• Pregnancy
Involve young people
in design of service
Ensure transition support is
developmentally appropriate
Ensure transition support
is strengths-based
Implement centered
approach
Perform gap
analysis
Planning a
service
Planning for
transition
Named
worker
Access to peer
support
Building
independence
Involve parents
and carers
Timing
appropriate
Before
transition
Multi-disciplinary
team
Shared datawith
adult services
Outline services
available
Joint clinics with
adult team
Fig. 3 Flow chart of the stages in planning transition. Various factors
should be considered before the young person is actually transitioned to
adult services. The timing of transition is critical and should be
individualized according to the assessment of the multi-disciplinary team.
Box 1 Quotes from patients, carers and other family members on the ideal
features of a transition clinic. Seeing older patients in clinic waiting areas
who might be in the advanced stages of the same condition is scary.
Understanding that there are other conditions in the same clinic, or that
treatments have changed, helps to remove some of the fear. Young people
are often used to being told off and will sometimes try to avoid this by
simply not going to an appointment if they are running late. Knowing
who they can contact can help prevent this. Will we see one of a team or a
named Consultant? I’d like to see the same person for the first few ap-
pointments so that we can establish a good relationship.
Rev Endocr Metab Disord
Over the last few years, numerous medications have been
tried in children with HH [201]. For instance long-acting so-
matostatin analogues and mTOR inhibitors (sirolimus) have
been used in various groups of children with varied response
[133–136, 140–142, 148]. There is potential use of insulin
receptor antagonists as a therapeutic approach to control hy-
poglycemia in CHH [202, 203]. Also, reports have document-
ed the use of a stable form of glucagon in adults with hypo-
glycemia [159, 160], however more clinical trials are required
to prove its efficacy in children with HH.
Besides the development of new diagnostic tools and ther-
apeutic agents, clinicians need to become involved in creating/
potentiating HH transition clinics to provide optimal ongoing
care into adulthood for these patients.
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